Will new AR inhibitors reshape the prostate cancer landscape?
Mené sur 134 patients atteints d'un cancer métastatique de la prostate résistant à la castration, cet essai international de phase I/II évalue l'efficacité et la toxicité d'un nouvel inhibiteur du récepteur des androgènes (ODM-201) en monothérapie
Non-steroidal androgen receptor (AR) inhibitors such as flutamide, nilutamide, and bicalutamide—commonly known as anti-androgens—have been used for several decades to treat prostate cancer. The precursor flutamide was developed in the early 1970s and its first use in castration-resistant prostate cancer was reported in 1975. In 1995, Labrie and colleagues postulated that the production of adrenal androgens might fuel prostate cancer cells in a castrated environment and suggested that complete or ...
The Lancet Oncology , commentaire, 2013